Lecankitug Biosimilar Monoclonal Antibody (IL-17A / IL-17F) for Research

Cat No.: GMP-Bios-INN-1254

Anti-IL17A&IL17F therapeutic antibody (Pre-made Lecankitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lecankitug (development codes LZM-012/XKH004) is a humanized monoclonal antibody targeting IL-17A and IL-17F. It is developed for inflammatory conditions. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1254-1mg 1mg 3090
GMP-Bios-INN-1254-10mg 10mg
GMP-Bios-INN-1254-100mg 100mg
GMP-Bios-INN-1254-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Lecankitug biosimilar, Whole mAb, Anti-IL17A&IL17F Antibody: Anti-IL-17A/IL17A/IL17/Interleukin-17A therapeutic antibody
INN Name Lecankitug
Target IL17A&IL17F
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC